<DOC>
	<DOCNO>NCT00992485</DOCNO>
	<brief_summary>Up date , sure cure Crohn 's fistula know fistula recurrence rate high . On 15 October 2008 , orphan drug designation grant Korea FDA Anterogen Co. Ltd. , human adipose-derived stem cell . In study , patient give injection ADIPOPLUS fistula site follow 8 week test safety efficacy .</brief_summary>
	<brief_title>Safety Efficacy Study Autologous Cultured Adipose -Derived Stem Cells Crohn 's Fistula</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<criteria>Older 18 year Prior diagnosis Crohn 's disease patient Crohn 's fistula negative urine betaHCG woman childbearing age agreement participate , sign informedconsent patient allergy bovinederived material anesthetic patient diagnosis auto immune disease except Crohn 's disease Diagnosis HBV , HCV , HIV infectious disease Patients symptom septicemia Patients diagnosis active Tuberculosis Patients pregnant breastfeeding Patients unwilling use `` effective '' method contraception study Patients diagnosis Inflammatory Bowel Disease except Crohn 's disease Patients sensitive Fibrin glue Patients clinically relevant history abuse alcohol drug Insufficient adipose tissue manufacture ADIPOPLUS Patients consider suitable study investigator Patients history surgery malignant cancer past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>